Narrow search
Showing 1 - 10 of 197
Cover Image
Cardiovascular drug shortages in Lebanon : a broken heart
Khattar, Georges; Hallit, Jennifer; El Chamieh, Carolla; … - In: Health economics review 12 (2022) 1, pp. 1-2
For nearly 3 years now, Lebanon has been assailed by compounded crises. With the economic instability, the coronavirus pandemic, and the explosion of the Beirut Port on August 4, 2020; the fragile Lebanese healthcare system has found itself at massive risk of a catastrophic public health crisis...
Persistent link: https://www.econbiz.de/10013198765
Cover Image
The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany
Dintsios, C. M.; Beinhauer, I. - In: Health economics review 10 (2020) 7, pp. 1-25
Background: We analysed the impact of clinical study design for oncological pharmaceuticals on the subsequent price … Health Insurance Funds. The analysis was conducted for all oncology pharmaceuticals that underwent the early benefit …. Further analyses should be performed when more oncology pharmaceuticals have passed the early benefit assessment. …
Persistent link: https://www.econbiz.de/10012291135
Cover Image
Implementing personalized medicine with asymmetric information on prevalence rates
Antoñanzas Villar, Fernando; Juárez-Castelló, Carmelo A. - In: Health economics review 6 (2016) 35, pp. 1-8
Although personalized medicine is becoming the new paradigm to manage some diseases, the economics of personalized medicine have only focused on assessing the efficiency of specific treatments, lacking a theoretical framework analyzing the interactions between pharmaceutical firms and healthcare...
Persistent link: https://www.econbiz.de/10011586604
Cover Image
Pharmaceutical regulation in Europe and its impact on corporate R&D
Eger, Stephan; Mahlich, Jörg C. - In: Health economics review 4 (2014) 23, pp. 1-9
Objectives: Many European countries regulate the markets for prescription drugs in order to cope with rising health expenditures. On the other hand, regulation distorts incentives to invest in pharmaceutical R&D. This study aims at empirically assessing the impact of regulation on pharmaceutical...
Persistent link: https://www.econbiz.de/10010526909
Cover Image
Trajectories of prices in generic drug markets : what can we infer from looking at trajectories rather than average prices?
Trujillo, Antonio J.; Gutierrez, Jose C.; Garcia … - In: Health economics review 12 (2022) 1, pp. 1-12
Background: Well-functioning competitive markets are key to controlling generic drug prices. This is important since over 90% of all drugs sold in the US are generics. Recently, there have been examples of large price increases in the generic market. Methods: This paper examines price...
Persistent link: https://www.econbiz.de/10013329485
Cover Image
Direct and indirect savings from parallel imports in Sweden
Granlund, David - In: Health economics review 12 (2022) 1, pp. 1-14
EUR) per year. In total, parallel imports reduced the cost for on-patent pharmaceuticals by 4%. When discounts were …
Persistent link: https://www.econbiz.de/10013490959
Cover Image
The effects of drug market regulation on pharmaceutical prices in Europe : overview and evidence from the market of ACE inhibitors
Schulenburg, Fritz von der; Vandoros, Sotiris; Kanavos, … - In: Health economics review 1 (2011) 18, pp. 1-8
in reducing pharmaceuticals prices. Results are not as strong for demand side measures. Profit controls and the use of …
Persistent link: https://www.econbiz.de/10009503923
Cover Image
Benefit assessment in Germany : implications for price discounts
Theidel, Ulrike; Schulenburg, Johann-Matthias von der - In: Health economics review 6 (2016) 33, pp. 1-12
Background: The AMNOG regulation, introduced in 2011 in Germany, changed the game for new drugs. Now, the industry is … of this evaluation is to identify factors influencing the results of the AMNOG price negotiation process. Methods: The … discount. Conclusions: Although the AMNOG regulation implemented binding and strict rules for the benefit assessment itself …
Persistent link: https://www.econbiz.de/10011586599
Cover Image
How innovation can be defined, evaluated and rewarded in health technology assessment
Rejon-Parrilla, Juan Carlos; Espin, Jaime; Epstein, David - In: Health economics review 12 (2022) 1, pp. 1-11
Background: What constitutes innovation in health technologies can be defined and measured in a number of ways and it has been widely researched and published about. However, while many countries mention it as a criterion for pricing or reimbursement of health technologies, countries differ...
Persistent link: https://www.econbiz.de/10012804110
Cover Image
The role of Iran's context for the development of health technology assessment : challenges and solutions
Behzadifar, Meysam; Behzadifar, Masoud; Saran, Maryam; … - In: Health economics review 13 (2023) 1, pp. 1-7
Health technology assessment (HTA) is a comprehensive and structured evaluation that aims to analyze the potential … impacts of health technologies, including medical devices, diagnostic tools, pharmaceuticals, and public health interventions … implementation of these technologies. HTA allows for the comparison of various scenarios related to a technology across a wide range …
Persistent link: https://www.econbiz.de/10014500317